The GLP is committed to full transparency. Download and review our Annual Report.

‘Genetic crapshoot’: Two studies suggest clinical use of CRISPR hampered by off-target editing

| | March 7, 2019

The version of CRISPR whose selling point has been its precision suffers, ironically, from the same shortcoming that has dogged other forms of the genome editor — that it makes a lot of unintended, off-target DNA changes. In two studies published [February 28], one in mice embryos and one in rice plants, scientists find that this “base editing,” a form of CRISPR invented in 2016, can cause hundreds of unintended mutations, potentially making its clinical use a genetic crapshoot.

Fears about off-target mutations from CRISPR have waxed and waned even as clinical development of CRISPR [marches on.]

[T]he latest research is being received cautiously. “I really like these studies and think they advance the field,” said biochemist David Liu of Harvard University, who invented base editing three years ago. They show that there are reliable ways to detect off-target editing, he said, and should light a fire under scientists to figure out ways to minimize it.

Related article:  Viewpoint: Congressional proposal to loosen court ruling that blocked companies from patenting genes could 'stifle' science innovation

But details of the mouse study, in particular, “make me suspect that this is a worst-case scenario,” Liu said. He welcomed that, however, saying it suggests the outer limits of base editors’ flaws.

Read full, original post: CRISPR base editing, known for precision, hits a snag with off-target mutations

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend